Daito Pharmaceutical Co., Ltd. (4577) Stock Price

Daito is a pharmaceutical company whose main business is manufacturing and selling active pharmaceutical ingredients (raw materials for medicines) and formulations (prescription and over-the-counter drugs). The company has established an integrated production system that can manufacture everything from raw materials to final formulations, meeting diverse pharmaceutical needs.

Its primary customers are domestic and international pharmaceutical manufacturers, generic drug makers, and major pharmaceutical companies. Product sales and contract manufacturing form the core of its revenue. In addition to supplying its own developed products, the company expands its sales channels through joint development with other companies and partnerships with firms that have strong sales capabilities. It also pursues overseas expansion through export support and local subsidiaries.

The business is divided into three main segments: ①manufacturing and selling active pharmaceutical ingredients, ②manufacturing and selling formulations for medical and general use, as well as contract manufacturing, and ③selling health foods and pharmaceutical-related products. The company maintains quality control that meets Japanese GMP standards as well as U.S. and European standards. It supports its operations through production facilities capable of flexible responses ranging from mass production to small-volume, multi-product manufacturing, and through overseas bases.

Under its medium-term management plan "DTP2027 (Daito Transformation Plan 2027)," the company aims to improve performance and enhance corporate value. Specifically, it has set consolidated earnings targets for the fiscal year ending May 2026 of 52.5 billion yen in revenue, 3.0 billion yen in operating profit, 3.0 billion yen in ordinary profit, and 2.3 billion yen in net income attributable to parent company shareholders. The company plans to improve capital productivity by setting KGIs and KPIs and enhancing ROIC and ROE. Regarding shareholder returns, the company acquired and cancelled 300,000 treasury shares in 2025, and has decided to increase dividends and introduce a shareholder benefit program for fiscal 2026, while also addressing PBR below 1.0 and advancing capital allocation sophistication.

Priority investment areas include efficiency improvements in existing operations and a shift toward higher-value-added products, strengthening the China business, entry into new businesses, and investment in human capital. The Portfolio Management Division, established in September 2024, is advancing product "selection and concentration," and has introduced a demand-supply planning process combining sales and production to improve production efficiency and reduce inventory. Additionally, from June 2025, the company is discussing product consolidation and production facility consolidation under a "New Consortium Initiative" with Meiji Seika Pharma to achieve economies of scale and improved stable supply capacity. The company plans to expand high-margin products using the production capacity freed up by these measures.

In international expansion, the company positions the China market as an important growth area, leveraging the "Japanese quality, China cost" advantage built through 15 years of local investment and partnerships. Since a subsidiary's initial shipment of its own generic formulation (pregabalin capsules) to China in May 2025, the company has received additional orders and is considering contract manufacturing of approximately 11 generic active ingredients for the Chinese domestic market by May 2027. In parallel, the company is strengthening its local sales structure and advancing regulatory approvals to establish China operations as a profit pillar for the group.

The company is also focusing on technological innovation and quality improvement, positioning its integrated production system from active pharmaceutical ingredients to formulations and its quality management capability to continuously pass U.S. FDA inspections as competitive differentiators. In new areas, the company is entering the development and contract manufacturing of orphan drugs for rare diseases, and has concluded a development agreement for "NPC-29," a ubiquinol-containing formulation targeting multiple system atrophy, based on an agreement with Nobel Pharma, advancing development with a focus on Japan, the United States, and Europe. Additionally, through investments in employee education—including wage increases in Toyama, e-learning platform "Daito Learning," and engagement surveys—the company is strengthening technical capabilities and operational quality across the organization.